1. Macedo-Souza LI, Kok F, Santos S, et al. Spastic paraplegia, optic atrophy, and neuropathy is linked to chromosome 11q13. Ann Neurol. 2005;57(5):730-737.
2. Macedo-Souza LI, Kok F, Santos S, et al. Spastic paraplegia, optic atrophy, and neuropathy: new observations, locus refinement, and exclusion of candidate genes. Ann Hum Genet. 2009;73(Pt 3):382-387.
3. Melo US, Macedo-Souza LI, Figueiredo T, et al. Overexpression ofKLC2due to a homozygous deletion in the non-coding region causes SPOAN syndrome. Hum Mol Genet. 2015:ddv388.
4. Melo US, Macedo-Souza LI, Figueiredo T, et al. Overexpression ofKLC2due to a homozygous deletion in the non-coding region causes SPOAN syndrome. Hum Mol Genet. 2015: ddv388.
5. Santos S, Kok F, Weller M, de Paiva FRL, Otto PA. Inbreeding levels in Northeast Brazil: strategies for the prospecting of new genetic disorders. Genet Mol Biol. 2010;33(2):220-223.
6. Lo Giudice T, Lombardi F, Santorelli FM, Kawarai T, Orlacchio A. Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. Exp Neurol. 2014;261:518-539.
7. Graciani Z, Santos S, Macedo-Souza LI, et al. Motor and functional evaluation of patients with spastic paraplegia, optic atrophy, and neuropathy (SPOAN). Arq Neuropsiquiatr. 2010;68(1):3-6.
8. Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989;42(8):703-709.
9. Schule, R., Holland-Letz, T., Klimpe, S., Kassubek, J., Klopstock,¨ T., Mall, V., Otto, S., Winner, B. & Schols, L. (2006) The Spastic¨ Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity. Neurology 67, 430–434
10. Fink J. Advances in the hereditary spastic paraplegias. Exp Neurol. 2003;184:106-110.
11. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206-207.
12. Carr JH, Shepherd RB, Nordholm L, Lynne D. Investigation of a new motor assessment scale for stroke patients. Phys Ther. 1985;65(2):175-180.
13. Smith AW, Jamshidi M, Lo SK. Clinical measurement of muscle tone using a velocity-corrected modified Ashworth scale. Am J Phys Med Rehabil. 2002;81(3):202-206.
14. Chiaravalloti ND, DeLuca J. Assessing the behavioral consequences of multiple sclerosis: an application of the Frontal Systems Behavior Scale (FrSBe). Cogn Behav Neurol. 2003;16(1):54-67.
15. Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJGM, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134(Pt 11):3167-3175.
16. Verhamme C, van Schaik IN, Koelman JHTM, de Haan RJ, de Visser M. The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain. 2009;132(Pt 12):3252-3262.
17. Dalakas MC. Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006;2(8):437-447.
18. Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology. 2000;55(9):1385-1387.
19. Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in Inclusion Body Myositis. Am J Phys Med Rehabil. 2008;87(11):883-889.
20. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9(2):177-189.
21. Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology. 2000;55(2):296-298.
22. Rinaldi F, Motti D, Ferraiuolo L, Kaspar BK. High content analysis in amyotrophic lateral sclerosis. Mol Cell Neurosci. 2017;80:180-191.
23. Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989;42(8):703-709.